International Journal of Immunology is a peer-reviewed open access journal that publishes original research articles as well as review articles in all areas of immunology. Immunology is a diverse and growing discipline that can be defined as the study of the tissues, cells and molecules involved in host defense mechanisms. Immunologists attempt to understand how the immune system develops, how the body defends itself against disease, and what happens when it all goes wrong. Priority is given to work that provides fundamental insight into the workings of the immune system. Areas covered include, but are not limited to, innate immunity and inflammation; development; immune receptors, signaling and apoptosis; antigen presentation; gene regulation and recombination; cellular and systemic immunity; vaccines; immune tolerance; autoimmunity and tumor immunology, microbial immunopathology; and transplantation.
The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in biological sciences. This remarkable growth is stimulated by the influx of investigators from other disciplines such as biochemistry, genetics, molecular biology, microbiology, virology and various medical disciplines. These disciplines are so well interlinked with immunology that no immunological challenge can now be properly addressed without sophisticated applications of expertise of combinations of these disciplines. As a consequence, immunology has become a vast and rich field encompassing discoveries and outlooks that range from the highly clinical to the highly molecular. Although such perspectives may appear diverse, they are, in fact, extremely interdependent. The journal seeks to present a balanced overview of contemporary immunology and melds together different aspects of molecular immunology, immunobiology and clinical immunology.
Immunology is the branch of biomedical science that deals with the response of an organism to antigenic challenge and its recognition of what is self and what is not. It deals with the defense mechanisms including all physical, chemical and biological properties of the organism that help it to combat its susceptibility to foreign organisms, material, etc
Immunology has its origins in the study of how the body protects itself against infectious diseases caused by microorganisms, such as bacteria, viruses, protozoa, and fungi, and also parasitic organisms, such as helminth worms. Research / review articles deals with, among other things, the physiological functioning of the immune system in states of both health and disease; malfunctions of the immune system in immunological disorders (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection); the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo are of prime interest.
We take great pleasure in welcoming you to our new journal, International Journal of Immunology. We have created this publication with the intention of providing a space for the generation of knowledge, dialogue, critique, debate, and collaboration among an international community of immunologists, pathologists, researchers, scholars, etc.
Our vision is to create a high-quality publication that will be relevant, challenging, thought-provoking, for graduate students, academic researchers and scholars. We welcome original research papers, reviews articles, case studies, book reviews, and works-in progress.
We look forward to welcoming your submissions.
1. Adaptive immunity 11. Cancer and Tumor Immunobiology
2. Immunologic Techniques 12. Cellular & Regional Immunology
3. Transplantation Immunology 13. Combining Cancer Immunotherapies
4. Computational Immunology 14. Allergy prevention and risk factors
5. Immunology 15. Nutritional Immunology
6. Immunotherapy 16. Clinical Immunology
7. Pediatric Immunology 17. Reproductive Immunology
8. Immune Tolerance 18. Fungal Immunology
9. Mucosal Immunology 19. Neuro Immunology
10. Immune Toxicology 20.Immunoinformatics and System
Immune Scientific Networks:
Immunology Leadership & Committees consider proposals for Special Issues Editors will return a decision on your proposal within Two weeks of receipt. To enrich our vision of making the scientific information available at an ease of access, Immunology Leadership & Committees initiated special issue for the open access journals. All the articles published under a special issue focuses on a single topic providing the complete information about the ongoing research providing more insight on an emphasized topic of research enabling the readers access wide forecasted information on a particular topic Issue.
Special Issue Proposals: Special Issue deals with focused research topics of high interest, falling under the scope of the Journal. Special Issues are the pool of articles under a current topic selected from the Ongoing Research under specific discipline. The aim of the Special Issue is to provide a platform for the researchers to understand the recent advancements and challenges in particular areas of research. These articles will provide an opportunity to the readers to understand and access the scientific information.
We encourage potential scientists to organize the Special Issue in their field of interests that fits within the Journal scope. This will provide an opportunity to increase the visibility of the Guest Editors. The Special Issue Titles may be from any basic and clinical area of Science, Technology and Medicine. People interested in publishing a special issue are advised to consider the following guidelines.
Your proposal should contain:
By submitting a Special Issue proposal to Immunology Leadership & Committees, you agree to abide by the Special Issue Editor Protocol should your proposal be accepted
Special issue articles are published immediately upon their acceptance and are released under upcoming regular issues. Special Issues are invited throughout the year. For more information or any queries about the special issues, please write us to email@example.com or firstname.lastname@example.org
Promoting Your Special Issue
Immunology Leadership & Committees will work with Guest Editors to increase the visibility of the Special Issue in the months leading up to the submission deadline and once it has been published.
What Immunology Leadership & Committees will do:
1. Immunology Leadership & Committees will circulate your Call for Papers to the Immune Editorial Board, targeted mailing lists, and relevant AoM listservs. It will also advertise your Call on the Immune websites and other social media platforms. It will re-issue the Call at appropriate intervals.
2. Once the Special Issue is published, announcements will be made to the Immune Editorial Board, targeted mailing lists, and relevant AoM listservs as well as on the Immune websites social media platforms.
3. Free access to the Special Issue will be made available in the website to Guest Editors and readers.
What is expected of Guest Editors?
1. We expect that Guest Editors will circulate the Call for Papers within their own personal networks, social media groups, and at any relevant conferences or workshops they may attend.
2. If it has not already been suggested as part of the proposal, consideration should be given to organizing a conference or workshop either to generate submissions or to aid in the development of submitted papers. A symposium or PDW at a well-known conference may also be considered.
3. We expect Guest Editors to identify up to 50 scholars for whom the Special Issue will be particularly relevant
If you have any queries, please contact Elena Griffin (email@example.com)
9/01/1981-8/31/1986 M.D. (Equivalent) The FourthMilitaryMedicalUniversity, Xi'an, China
9/01/1986-8/31/1989 Master of Medical Sciences (Equivalent to Specialist Fellowship) Medical Oncology/Gastroenterology, Institute of Gastroenterology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China
9/01/1989-8/31/1992 Ph.D. Tumor biology/Molecular immunology, Institute of Gastroenterology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Dissertation title: Tumor-targeted therapy by immunoliposomes targeting human gastric cancer. Mentor: Dr. Xue-yong Zhang, Professor and Chairman of Internal Medicine.
9/01/1992-4/30/1994 Resident/Clinical Fellow, Specialty: Medical Oncology and Gastroenterology. Department of Gastroenterology/Oncology, XijingHospital, The FourthMilitaryMedicalUniversity, Xi'an, China
5/1/1994-1/31/1996 Post-doctoral Research Fellow, Experimental Immunology Unit, Faculty of Medicine, University of Louvain, Clos Chappelle-aux-Champs 30-56, B-1200 Brussels, Belgium (Supported by European Union Marie Curie Fellowship)
2/1/1996-9/30/1996 Post-doctoral Research Fellow, Department of Surgery/ Otolaryngology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305
10/1/1996-12/31/1997 Post-doctoral Research Fellow, Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC
Precision cancer medicine targeting cancer and cancer stem cells, via novel nanovectors and rational drug design
1) Novel small-molecule cancer therapeutics - Drug discovery and molecular cancer therapy.
My lab has been working on drug discovery for novel small molecule cancer therapeutics targeting cell signaling pathways, especially for cancer cell chemo/radiosensitization by molecular modulation of apoptosis/autophagy/necroptosis. I have >25 issued / pending patents and was involved in four successful INDs, all are now in advanced clinical trials for cancer. I was involved in the discovery and development of the first Bcl-2 inhibitor entered clinical trials, also a natural product that has completed Phase IIb trials.
Currently, I am working on molecular cancer drug discovery, using structure-based rational drug design fornovel small molecule inhibitors targeting Musashi-1/2 and HuR,the RNA-binding proteinscritical for chemo/radioresistance but are so far believed “undruggable”. Through high-throughput screening and lead optimization, we obtained nanomolar to submicromolar lead compounds, and provisional patents were filed. Our long-term goal is for further lead optimization to obtain more potent and specific, drug like leads for development as first-in-class Musashi-1/2 or HuR inhibitors as whole new therapy for cancer. The projects are funded by two NIH/NCI R01 grants and one DOD grant.
2) Novel nanovector delivery systems targeting cancer and cancer stem cells - Drug/gene delivery.
Funded by multiple NIH and DOD grants,my lab works on the tumor-targeted delivery of molecular cancer therapeutics using novel nanotechnology. A self-assembled, virus-mimicking, non-viral nanovector for non-viral tumor-targeted, systemic p53 gene therapy has shown promise in chemo/radiosensitization of breast, prostate, head and neck cancer, just completed a first-in-human Phase I clinical trial,now in multi-center Phase II Trials. Multiple US and International Patents are issued or pending. Currently, I amexploring next generation nanovectors for tumor-targeted delivery of siRNA/miRNA/CRISPR-based therapeutics for targeting cancer and cancer stem cells. Imaging-based nano-drug delivery for cancer targeted therapy will be my focus.
2008- International Journal of Clinical and Experimental Medicine
2009- American Journal of Translational Research
2010- American Journal ofCancer Research
2010- Journal of Carcinogenesis & Mutagenesis
2010- Cancer Science and Therapy
2011- Journal of Cancer Therapeutics and Research
2012- Oncology Discovery
2013- JSM Biotechnology & Biomedical Engineering
2014- Journal of Gastroenterology & Hepatology
2015- Journal of Cancer Science
2015- Journal of Clinical Radiation Oncology